These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 32420682

  • 21. Detection of factor IX inhibitors by immunoradiometric assay.
    Ljung R, Holmberg L.
    Acta Haematol; 1983; 70(5):307-11. PubMed ID: 6414224
    [Abstract] [Full Text] [Related]

  • 22. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M, Warrier I, Rajpurkar M, Lusher JM.
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [Abstract] [Full Text] [Related]

  • 23. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM, Pourfathollah A, Shooshtari MM, Yazdi ZR.
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
    Dargaud Y, Béguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C.
    Thromb Haemost; 2005 Mar; 93(3):475-80. PubMed ID: 15735797
    [Abstract] [Full Text] [Related]

  • 25. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
    Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K, RCPA Haematology QAP Haemostasis Committee.
    Haemophilia; 2010 Jul 01; 16(4):662-70. PubMed ID: 20070382
    [Abstract] [Full Text] [Related]

  • 26. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM, Sadeghi-Khomami A, Barnowski C, Wikén M, Willemze AJ.
    Int J Lab Hematol; 2020 Jun 01; 42(3):350-358. PubMed ID: 32202380
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V, Jouppila A, Lassila R.
    Int J Lab Hematol; 2017 Aug 01; 39(4):359-368. PubMed ID: 28406575
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
    Marlar RA, Strandberg K, Shima M, Adcock DM.
    Eur J Haematol; 2020 Jan 01; 104(1):3-14. PubMed ID: 31606899
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.
    Hua B, Wu R, Sun F, Luo B, Alvey C, Labadie R, Qu PR, Korth-Bradley JM, Rendo P.
    Thromb Haemost; 2017 Jun 02; 117(6):1052-1057. PubMed ID: 28331929
    [Abstract] [Full Text] [Related]

  • 40. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I, Hadhri S, El Omri H, Sassi R, Chaabani W, Ennabli S, Skouri H.
    Ann Biol Clin (Paris); 2012 Jun 02; 70(6):659-65. PubMed ID: 23207810
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.